$OVID
Ovid Therapeutics Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021027623 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $208.4M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.60M $5.700M
YoY Change 173.68% 21.28%
% of Gross Profit
Research & Development $16.25M $14.63M
YoY Change 11.1% 56.63%
% of Gross Profit
Depreciation & Amortization $74.74K $66.88K
YoY Change 11.75% -12.62%
% of Gross Profit
Operating Expenses $31.83M $20.29M
YoY Change 56.82% 44.41%
Operating Profit $176.6M -$20.29M
YoY Change -969.98% 44.41%
Interest Expense $0.00 $300.0K
YoY Change -100.0% 0.0%
% of Operating Profit 0.0%
Other Income/Expense, Net $264.3K
YoY Change 4.32%
Pretax Income $176.5M -$20.03M
YoY Change -981.21% 45.15%
Income Tax $500.3K
% Of Pretax Income 0.28%
Net Earnings $176.0M -$20.03M
YoY Change -978.71% 45.14%
Net Earnings / Revenue 84.46%
Basic Earnings Per Share $2.55 -$0.37
Diluted Earnings Per Share $2.53 -$0.37
COMMON SHARES
Basic Shares Outstanding 66.09M 54.72M
Diluted Shares Outstanding 66.58M 54.72M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $233.1M $58.33M
YoY Change 299.6% -2.19%
Cash & Equivalents $233.1M $27.34M
Short-Term Investments $31.00M
Other Short-Term Assets $2.600M $2.000M
YoY Change 30.0% 5.26%
Inventory
Prepaid Expenses
Receivables $1.000M $400.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $236.7M $60.74M
YoY Change 289.71% -3.28%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $109.0K
YoY Change -8.29% 64.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $436.3K
YoY Change -8.32% 31.77%
Total Long-Term Assets $800.0K $985.7K
YoY Change -18.84% -74.43%
TOTAL ASSETS
Total Short-Term Assets $236.7M $60.74M
Total Long-Term Assets $800.0K $985.7K
Total Assets $237.5M $61.72M
YoY Change 284.78% -7.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M $3.992M
YoY Change -22.35% -9.49%
Accrued Expenses $13.20M $5.989M
YoY Change 120.41% 63.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.30M $9.992M
YoY Change 63.13% 23.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $300.0K
YoY Change -100.0% -76.92%
Total Long-Term Liabilities $0.00 $300.0K
YoY Change -100.0% -76.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.30M $9.992M
Total Long-Term Liabilities $0.00 $300.0K
Total Liabilities $16.35M $10.28M
YoY Change 59.03% 9.23%
SHAREHOLDERS EQUITY
Retained Earnings -$118.2M -$233.2M
YoY Change -49.32% 40.06%
Common Stock $339.3M $284.6M
YoY Change 19.23% 27.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $221.1M $51.44M
YoY Change
Total Liabilities & Shareholders Equity $237.5M $61.72M
YoY Change 284.71% -7.4%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $176.0M -$20.03M
YoY Change -978.71% 45.14%
Depreciation, Depletion And Amortization $74.74K $66.88K
YoY Change 11.75% -12.62%
Cash From Operating Activities $160.9M -$18.41M
YoY Change -973.89% 43.1%
INVESTING ACTIVITIES
Capital Expenditures $11.51K $14.14K
YoY Change -18.57% 226.99%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.000M
YoY Change -100.0%
Cash From Investing Activities -$11.51K $3.836M
YoY Change -100.3% -42844.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 129.7K 15.54K
YoY Change 734.64% -99.95%
NET CHANGE
Cash From Operating Activities 160.9M -18.41M
Cash From Investing Activities -11.51K 3.836M
Cash From Financing Activities 129.7K 15.54K
Net Change In Cash 161.0M -14.56M
YoY Change -1205.87% -180.4%
FREE CASH FLOW
Cash From Operating Activities $160.9M -$18.41M
Capital Expenditures $11.51K $14.14K
Free Cash Flow $160.9M -$18.43M
YoY Change -973.16% 43.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10169887
CY2021Q1 us-gaap Liabilities
Liabilities
16346090
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
67788
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339226941
CY2021Q1 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
1023791
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
221109940
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75925518
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2212892
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118184790
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294192097
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
43631656
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237456030
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67787826
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65743170
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67787826
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65743170
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
208382779
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
176557316
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-49732
CY2020Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
264296
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
176507584
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20030090
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500277
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-20030090
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.55
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.53
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66088592
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54715610
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66578377
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54715610
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
176007307
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19966855
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
70023561
CY2020Q1 ovid Atm Offering Costs
ATMOfferingCosts
2053
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1302931
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
83110
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
63235
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
51444800
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1320002
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1302931
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66879
CY2020Q1 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-130328
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
86809
CY2020Q1 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-18446
CY2021Q1 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
882028
CY2020Q1 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
-756894
CY2021Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-225116
CY2020Q1 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-72969
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2277334
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1277734
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12382779
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2432192
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
160899083
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1165847
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18411729
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9961092
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14000000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11514
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14139
CY2020Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
188842
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11514
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3835927
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
130173
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
83110
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20802
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129661
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15535
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
161017230
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14560267
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41897144
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233051160
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27336877
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(C) Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2021Q1 ovid Working Capital
WorkingCapital
220300000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
221000000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
185337
CY2021Q1 us-gaap Depreciation
Depreciation
19000
CY2020Q1 us-gaap Depreciation
Depreciation
12000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
263000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
319000
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
233051160
CY2021Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
233051160
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
72033930
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72033930
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 ovid Debt Securities Available For Sale Continuous Unrealized Gain Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
203980
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55000
CY2021Q1 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
2211228
CY2020Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
4175497
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1194988
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3845441
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9119031
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3846211
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
673285
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165536
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share held
CY2020Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
46700000
CY2021Q1 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
Holders of Series A preferred stock are entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends (other than dividends in the form of the issuance of common stock) actually paid on shares of common stock.
CY2021Q1 us-gaap Dividends
Dividends
0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1320002
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302931
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10403420
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
643600
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10400
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
28439
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11008181
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5824393
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.26
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.18
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.00
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.52
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.15
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.35
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M2D
CY2021Q1 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y5M19D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y11M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
652438
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6836
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6453789
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2522609
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12400000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20030090
CY2020Q1 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0
CY2021Q1 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-7439355
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
168567952
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M26D
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0028
CY2021Q1 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
500000
CY2021Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
489784

Files In Submission

Name View Source Status
0001564590-21-027623-index-headers.html Edgar Link pending
0001564590-21-027623-index.html Edgar Link pending
0001564590-21-027623.txt Edgar Link pending
0001564590-21-027623-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gvedip405tty000001.jpg Edgar Link pending
ovid-10q_20210331.htm Edgar Link pending
ovid-20210331.xml Edgar Link completed
ovid-20210331.xsd Edgar Link pending
ovid-20210331_cal.xml Edgar Link unprocessable
ovid-20210331_def.xml Edgar Link unprocessable
ovid-20210331_lab.xml Edgar Link unprocessable
ovid-20210331_pre.xml Edgar Link unprocessable
ovid-ex101_428.htm Edgar Link pending
ovid-ex311_9.htm Edgar Link pending
ovid-ex312_6.htm Edgar Link pending
ovid-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending